A Phase 2 interventional study of Plecanatide and Matching placebo in Chronic Idiopathic Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 36 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-10-04.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.
Among the 12 studies testing plecanatide in Constipation, this one is the 11th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 2, and was the 9th registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →
plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 7
First in 2010; this study’s year is marked. 1 started in 2017.
This study's enrollment of 124 is above the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 800 across the 12 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 2 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
21 studies in Constipation by Bausch Health Companies Inc.: none open now, 1 under way, none of them phase 3. Of 20 finished, 15 (75%) have results posted.
Among the 21 studies in Constipation by Bausch Health Companies Inc., this one is the 15th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2017, is one of 9 in phase 2, and was the 18th registered.
Bausch Health Companies Inc.’s Constipation studies by the year they started, since 2006.
1 of the studies testing plecanatide in Constipation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07723924Bausch Health Americas, Inc.This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC | 2027-10-18 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing plecanatide in Constipation, from their registry updates:
Among Bausch Health Companies Inc.’s 21 in Constipation:
This tab as a report to print or save as PDF → With an account.
This is a study of efficacy and safety of Plecanatide in pediatric subjects aged 12 to \< 18 years diagnosed with Chronic Idiopathic Constipation.
The purpose of the study is to evaluate efficacy, safety, and pharmacokinetics (PK) of oral Plecanatide 0.5, 1.0 and 1.5 mg tablets dosed once a day as compared to matching placebo, when administered for 8 weeks in adolescents with chronic idiopathic constipation.
This study will consist of a 4-week screening period, 8 weeks of treatment, and a 2-week follow-up. The study will assess the effects of Plecanatide on bowel movement frequency and other clinical features of CIC.
Key Inclusion Criteria:
Key Exclusion Criteria:
The patient, if female of (defined as postmenarche), does not agree to practice 1 of the following medically acceptable methods of throughout the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Taken orally once daily in the morning for 8 weeks
Drug: Plecanatide
Taken orally once daily in the morning for 8 weeks
Drug: Plecanatide
Taken orally once daily in the morning for 8 weeks
Drug: Plecanatide
Taken orally once daily in the morning for 8 weeks
Drug: Matching placebo
Also known as: Trulance
Also known as: No other names
Proportion of Overall Responders
An Overall Responder is a participant who was a Spontaneous Bowel Movement (SBM) responder for the last 2 weeks of the Treatment Period. An SBM responder is defined as a participant who had \>3 SBMs per week. SBM was defined as a bowel movement that occurs in the absence of laxative use within the preceding 24 hours. Participants missing with respect to the outcome measure were scored as non-responders.
Time frame: 8 weeks
Change From Baseline in Weekly Average Stool Consistency Bristol Stool Form Scale (BSFS) Score
Stool consistency was assessed via the 7-point (1-7) Bristol Stool Form Scale (BSFS) and recorded in the bowel movement (BM) and Symptom Diaries. Lower numbers represent more formed stools; higher numbers represent less formed stools. The weekly mean BSFS score per patient = (total of all BSFS scores reported for a corresponding Spontaneous Bowel Movement (SBM) per time period)/n, where n = number of SBMs scored during the time period. Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. BSFS types were 1) separate hard lumps, like nuts (hard to pass); 2) sausage-shaped but lumpy; 3) like a sausage but with cracks on its surface; 4) like a sausage or snake, smooth and soft; 5) soft blobs with clear-cut edges (passed easily); 6) fluffy pieces with ragged edges, a mushy stool; 7) watery, no solid pieces, entirely liquid.
Time frame: 8 weeks
Change From Baseline in the Weekly Rate of Spontaneous Bowel Movements (SBM)
The weekly Spontaneous Bowel Movement (SBM) totals were derived from the daily diary entries reported during the Treatment Period in the Bowel Movement (BM) and symptom diaries. Baseline was the mean number of SBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. SBM is defined as a bowel movement that occurs in the absence of laxative use within the preceding 24 hours
Time frame: 8 weeks
Change From Baseline in the Weekly Rate of Complete Spontaneous Bowel Movements (CSBM)
The weekly Complete Spontaneous Bowel Movement (CSBM) totals are derived from the daily diary entries reported during the Treatment Period in the Bowel Movement (BM) and symptom diaries. Baseline is the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. Spontaneous Bowel Movement (SBM) was defined as a bowel movement that occurs in the absence of laxative use within the preceding 24 hours. CSBM was defined as a spontaneous bowel movement with the sense of complete evacuation.
Time frame: 8 weeks
| Milestone | Matching Placebo | Plecanatide 0.5 mg | Plecanatide 1.0 mg | Plecanatide 1.5 mg |
|---|---|---|---|---|
| Started | 31 | 31 | 30 | 32 |
| Completed | 27 | 27 | 26 | 29 |
| Not completed | 4 | 4 | 4 | 3 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 3 | 2 | 3 | 2 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
An Overall Responder is a participant who was a Spontaneous Bowel Movement (SBM) responder for the last 2 weeks of the Treatment Period. An SBM responder is defined as a participant who had \>3 SBMs per week. SBM was defined as a bowel movement that occurs in the absence of laxative use within the preceding 24 hours. Participants missing with respect to the outcome measure were scored as non-responders.
| Participants | Matching Placebo | Plecanatide 0.5 mg | Plecanatide 1.0 mg | Plecanatide 1.5 mg |
|---|---|---|---|---|
| Proportion of Overall Responders | 7 | 10 | 12 | 7 |
Stool consistency was assessed via the 7-point (1-7) Bristol Stool Form Scale (BSFS) and recorded in the bowel movement (BM) and Symptom Diaries. Lower numbers represent more formed stools; higher numbers represent less formed stools. The weekly mean BSFS score per patient = (total of all BSFS scores reported for a corresponding Spontaneous Bowel Movement (SBM) per time period)/n, where n = number of SBMs scored during the time period. Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. BSFS types were 1) separate hard lumps, like nuts (hard to pass); 2) sausage-shaped but lumpy; 3) like a sausage but with cracks on its surface; 4) like a sausage or snake, smooth and soft; 5) soft blobs with clear-cut edges (passed easily); 6) fluffy pieces with ragged edges, a mushy stool; 7) watery, no solid pieces, entirely liquid.
| units on a scale | Matching Placebo | Plecanatide 0.5 mg | Plecanatide 1.0 mg | Plecanatide 1.5 mg |
|---|---|---|---|---|
| Change From Baseline in Weekly Average Stool Consistency Bristol Stool Form Scale (BSFS) Score | 0.98 ± 0.209 | 1.09 ± 0.209 | 1.22 ± 0.205 | 1.06 ± 0.191 |
The weekly Spontaneous Bowel Movement (SBM) totals were derived from the daily diary entries reported during the Treatment Period in the Bowel Movement (BM) and symptom diaries. Baseline was the mean number of SBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. SBM is defined as a bowel movement that occurs in the absence of laxative use within the preceding 24 hours
| Weekly SBMs | Matching Placebo | Plecanatide 0.5 mg | Plecanatide 1.0 mg | Plecanatide 1.5 mg |
|---|---|---|---|---|
| Change From Baseline in the Weekly Rate of Spontaneous Bowel Movements (SBM) | 1.44 ± 0.332 | 1.97 ± 0.339 | 2.06 ± 0.343 | 2.05 ± 0.328 |
The weekly Complete Spontaneous Bowel Movement (CSBM) totals are derived from the daily diary entries reported during the Treatment Period in the Bowel Movement (BM) and symptom diaries. Baseline is the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. Spontaneous Bowel Movement (SBM) was defined as a bowel movement that occurs in the absence of laxative use within the preceding 24 hours. CSBM was defined as a spontaneous bowel movement with the sense of complete evacuation.
| Weekly CSBMs | Matching Placebo | Plecanatide 0.5 mg | Plecanatide 1.0 mg | Plecanatide 1.5 mg |
|---|---|---|---|---|
| Change From Baseline in the Weekly Rate of Complete Spontaneous Bowel Movements (CSBM) | 1.30 ± 0.344 | 1.71 ± 0.348 | 1.83 ± 0.354 | 2.11 ± 0.340 |
Collected over 8 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Matching Placebo | 0/31 (0%) | 0/31 (0%) | 4/31 (12.9%) |
| Plecanatide 0.5 mg | 0/31 (0%) | 0/31 (0%) | 7/31 (22.6%) |
| Plecanatide 1.0 mg | 0/30 (0%) | 0/30 (0%) | 4/30 (13.3%) |
| Plecanatide 1.5 mg | 0/32 (0%) | 0/32 (0%) | 3/32 (9.4%) |
| Event | Matching Placebo | Plecanatide 0.5 mg | Plecanatide 1.0 mg | Plecanatide 1.5 mg |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/31 | 2/31 | 2/30 | 1/32 |
| Viral upper respiratory tract infectionInfections and infestations | 0/31 | 0/31 | 1/30 | 0/32 |
| NeutropeniaBlood and lymphatic system disorders | 0/31 | 0/31 | 1/30 | 0/32 |
| Acute TonsillitisInfections and infestations | 1/31 | 0/31 | 0/30 | 0/32 |
| BronchitisInfections and infestations | 1/31 | 0/31 | 0/30 | 0/32 |
| Infectious MononucleosisInfections and infestations | 0/31 | 1/31 | 0/30 | 0/32 |
| Pharyngitis streptococcalInfections and infestations | 0/31 | 1/31 | 0/30 | 0/32 |
| Upper respiratory tract infectionInfections and infestations | 0/31 | 1/31 | 0/30 | 0/32 |
| Abdominal DiscomfortGeneral disorders | 1/31 | 0/31 | 0/30 | 0/32 |
| Gilbert's syndromeCongenital, familial and genetic disorders | 0/31 | 1/31 | 0/30 | 0/32 |
| Age, Continuous(years) | Matching Placebo | Plecanatide 0.5 mg | Plecanatide 1.0 mg | Plecanatide 1.5 mg | Total |
|---|---|---|---|---|---|
| Mean | 14.6 ± 1.61 | 15.1 ± 1.48 | 14.5 ± 1.89 | 14.6 ± 1.52 | 14.7 ± 1.62 |
| Sex: Female, Male(Participants) | Matching Placebo | Plecanatide 0.5 mg | Plecanatide 1.0 mg | Plecanatide 1.5 mg | Total |
|---|---|---|---|---|---|
| Female | 17 | 17 | 17 | 18 | 69 |
| Male | 14 | 14 | 13 | 14 | 55 |
| Ethnicity (NIH/OMB)(Participants) | Matching Placebo | Plecanatide 0.5 mg | Plecanatide 1.0 mg | Plecanatide 1.5 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 21 | 21 | 23 | 27 | 92 |
| Not Hispanic or Latino | 10 | 10 | 7 | 5 | 32 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Matching Placebo | Plecanatide 0.5 mg | Plecanatide 1.0 mg | Plecanatide 1.5 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 5 | 3 | 2 | 16 |
| White | 24 | 24 | 27 | 29 | 104 |
| More than one race | 1 | 1 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Matching Placebo | Plecanatide 0.5 mg | Plecanatide 1.0 mg | Plecanatide 1.5 mg | Total |
|---|---|---|---|---|---|
| United States | 31 | 31 | 30 | 32 | 124 |
| Baseline Stool Consistency(units on a scale) | Matching Placebo | Plecanatide 0.5 mg | Plecanatide 1.0 mg | Plecanatide 1.5 mg | Total |
|---|---|---|---|---|---|
| Mean | 2.17 ± 0.932 | 2.0 ± 1.190 | 2.08 ± .899 | 2.29 ± 1.298 | 2.13 ± 1.140 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2017 to primary completion in Sep 2018, 20 months.
Results were first posted in Sep 2019, 1 year after primary completion.
Of 24 industry-sponsored phase 2 interventional studies under Constipation, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's 20 months is close to that.
Counting every sponsor, half of 41 studies reached it within 20 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plecanatide
Bausch Health Americas, Inc. →